Immunoglobulin A (IgA) Deficiency (Selective Immunoglobulin A (IgA) Deficiency)

immunoglobulin A Deficiency — scientific infographic poster

Overview

Selective immunoglobulin A (IgA) deficiency (SIgAD) is the most common primary immunodeficiency worldwide, affecting approximately 1 in 300–500 individuals of Caucasian descent and 1 in 16,000 Japanese individuals — a striking ethnic variation that points to underlying genetic architecture. It is defined as a serum immunoglobulin A level below 7 mg/dL with normal serum immunoglobulin G (IgG) and immunoglobulin M (IgM) in patients aged 4 years or older, after excluding secondary causes.

Immunoglobulin A is the principal secretory immunoglobulin of the body's mucosal surfaces. Secretory immunoglobulin A (sIgA) is the dominant antibody in saliva, tears, colostrum, breast milk, intestinal secretions, and the respiratory mucosa — the very surfaces that act as the body's first-line barrier against pathogens. Despite being the most abundant antibody class produced each day (approximately 3–5 grams secreted daily across all mucosal surfaces combined), its absence is remarkably well tolerated in many individuals because serum immunoglobulin G and immunoglobulin M can partially compensate.

Partial immunoglobulin A deficiency is defined as serum immunoglobulin A between 7 mg/dL and 70 mg/dL with normal immunoglobulin G and immunoglobulin M. True selective immunoglobulin A deficiency requires immunoglobulin A below 7 mg/dL with normal immunoglobulin G and immunoglobulin M. When immunoglobulin G is also low, the diagnosis shifts toward common variable immunodeficiency (CVID), a more serious disorder that shares genetic overlap with SIgAD.

↑ Back to Table of Contents

Pathogenesis

The central defect in selective immunoglobulin A deficiency is a failure of B cell terminal differentiation. Immunoglobulin A-committed B cells are present and circulate in normal numbers, but they cannot complete the class-switch recombination to immunoglobulin A or fully mature into immunoglobulin A-secreting plasma cells. The block occurs late in B cell development — beyond the common lymphoid progenitor and class-switch machinery — making SIgAD distinct from agammaglobulinemias, where B cells are absent entirely.

Genetic associations: The strongest human leukocyte antigen (HLA) association is the A1-B8-DR3 haplotype, particularly common in Northern Europeans — explaining the high prevalence in Caucasian populations. Chromosomal deletions at 22q11.2 and 18q are identified in a subset of patients, especially those with additional dysmorphic features. Mutations in TACI (TNFRSF13B), encoding a B cell receptor for BAFF and APRIL, are found in a minority of both SIgAD and CVID patients, reinforcing the shared genetic substrate of these two conditions. Familial clustering occurs, and first-degree relatives of CVID patients have elevated rates of SIgAD.

Secondary (drug-induced) immunoglobulin A deficiency is clinically important because it is reversible. Implicated agents include phenytoin, valproate, sulfasalazine, captopril, D-penicillamine, and gold salts. The mechanism is thought to involve interference with cytokine signaling required for immunoglobulin A class switching. Discontinuing the offending drug typically leads to normalization of immunoglobulin A levels over months.

↑ Back to Table of Contents

Clinical Spectrum

One of the most striking features of selective immunoglobulin A deficiency is its clinical heterogeneity. The majority of affected individuals — estimates range from 50% to 85% — are entirely asymptomatic and are discovered incidentally when serum protein electrophoresis or immunoglobulin panels are ordered for unrelated reasons. For these individuals, the diagnosis may carry little practical consequence beyond the blood product risk described below.

Recurrent sinopulmonary infections are the most common symptomatic manifestation. Organisms that colonize mucosal surfaces — Streptococcus pneumoniae and Haemophilus influenzae — are the usual culprits. Affected individuals may have recurrent sinusitis, chronic otitis media, and pneumonia, sometimes progressing to bronchiectasis with repeated pulmonary infections over years.

Gastrointestinal manifestations deserve particular attention. Giardia lamblia is normally cleared from the small intestine by secretory immunoglobulin A; immunoglobulin A-deficient patients are highly susceptible to giardiasis and may suffer protracted, recurrent infections that are difficult to eradicate. Celiac disease occurs 10 times more often in immunoglobulin A-deficient patients than in the general population (discussed separately below). Inflammatory bowel disease and nodular lymphoid hyperplasia of the small bowel are additional gastrointestinal (GI) associations.

Autoimmune diseases are found in 20–30% of symptomatic patients. Systemic lupus erythematosus (SLE) is present in 10–15% of immunoglobulin A-deficient individuals. Rheumatoid arthritis, autoimmune thyroid diseases (both Hashimoto's thyroiditis and Graves' disease), vitiligo, type 1 diabetes mellitus, and autoimmune hepatitis are all overrepresented. The mechanism likely involves dysregulation of mucosal immune tolerance — the absence of secretory immunoglobulin A disrupts the normal suppression of immune responses to commensal antigens, tilting the balance toward autoimmunity.

Atopy is paradoxically increased. Asthma, allergic rhinitis, atopic dermatitis, and food allergies are more common in SIgAD patients, possibly because the absence of mucosal immunoglobulin A permits allergen penetration and aberrant Th2 sensitization at epithelial surfaces.

↑ Back to Table of Contents

Celiac Disease and Immunoglobulin A Testing

The intersection of immunoglobulin A deficiency and celiac disease creates a critical diagnostic trap that every clinician ordering celiac antibody tests must understand. Celiac disease occurs approximately 10 times more frequently in patients with selective immunoglobulin A deficiency than in the general population — making the co-occurrence far from rare. Yet the standard celiac screening tests are immunoglobulin A-based antibodies: anti-tissue transglutaminase immunoglobulin A (anti-tTG immunoglobulin A) and anti-endomysial immunoglobulin A (EMA-IgA). In a patient with immunoglobulin A deficiency, both of these tests will be falsely negative, even in the presence of active celiac disease with severe villous atrophy.

This false-negative result is not a testing error — it is a predictable consequence of the underlying immunodeficiency. When the immune system cannot produce immunoglobulin A, it cannot produce immunoglobulin A antibodies against tissue transglutaminase, regardless of how much gluten damage is occurring in the small intestine. A patient with unrecognized celiac disease and immunoglobulin A deficiency may receive a falsely reassuring celiac screen and go undiagnosed for years.

The solution is straightforward but requires awareness: always check total serum immunoglobulin A when ordering celiac antibody panels. If serum immunoglobulin A is low or undetectable, use immunoglobulin G-based celiac antibodies instead — anti-tTG immunoglobulin G and anti-deamidated gliadin peptide immunoglobulin G (anti-DGP immunoglobulin G). These tests retain their sensitivity for celiac disease even in immunoglobulin A-deficient patients. Small bowel biopsy (Marsh grading via duodenal histology) remains the gold standard and does not depend on immunoglobulin class.

Many major laboratory test requisitions now automatically reflexively report total immunoglobulin A when anti-tTG immunoglobulin A is ordered. Clinicians should verify that their laboratory follows this practice and interpret any immunoglobulin A-based celiac antibody result in the context of the patient's total serum immunoglobulin A level.

↑ Back to Table of Contents

Anti-IgA Antibodies and Blood Product Risk

Approximately 40% of patients with complete immunoglobulin A deficiency develop immunoglobulin E-class anti-IgA antibodies. These antibodies are directed against immunoglobulin A determinants that the patient's immune system has never seen — treating exogenous immunoglobulin A as foreign. When such a patient is exposed to immunoglobulin A-containing blood products, these pre-formed immunoglobulin E (IgE) anti-IgA antibodies can trigger immediate hypersensitivity reactions ranging from urticaria and flushing to severe, life-threatening anaphylaxis.

Blood products that contain immunoglobulin A include: whole blood, packed red blood cells, fresh frozen plasma, platelet concentrates, and most standard intravenous immunoglobulin (IVIG) preparations. Even trace amounts of immunoglobulin A in washed red blood cells or standard IVIG can be sufficient to trigger anaphylaxis in highly sensitized patients.

Safe management strategies:

It is worth noting that routine IVIG therapy is generally not indicated for uncomplicated SIgAD — secretory immunoglobulin A cannot be replaced by intravenous infusion, and the anaphylaxis risk outweighs the benefit for most patients. IVIG is reserved for the subset who develop CVID-like hypogammaglobulinemia or severe recurrent infections despite other measures.

↑ Back to Table of Contents

Evolution to CVID

Selective immunoglobulin A deficiency and common variable immunodeficiency (CVID) are not entirely separate diseases — they exist on a continuum of B cell maturation failure, sharing genetic underpinnings and clinical overlap. Approximately 15–20% of patients with SIgAD will eventually develop CVID over the course of years to decades. This transition is defined by a progressive decline in serum immunoglobulin G (and sometimes immunoglobulin M) to levels below normal, accompanied by increasing susceptibility to bacterial infections.

Monitoring: Because of this progression risk, annual measurement of serum immunoglobulin levels (immunoglobulin G, immunoglobulin A, immunoglobulin M) is recommended for all patients with SIgAD, particularly those who are symptomatic or who have relatives with CVID. A falling immunoglobulin G trajectory — even within the low-normal range — should prompt more frequent monitoring and consideration of prophylactic antibiotics or IVIG replacement.

Shared genetic architecture: TACI mutations (TNFRSF13B) are found in both conditions, and families have been described where some members have SIgAD and others have CVID — suggesting that additional genetic modifiers determine whether the defect remains limited to immunoglobulin A or expands to affect immunoglobulin G and immunoglobulin M production. Human leukocyte antigen associations (particularly HLA-DR3 and human leukocyte antigen-B8) are shared across both conditions in European populations.

Practical implication: a diagnosis of SIgAD should not be viewed as a static, benign finding. It is a marker of B cell immune dysfunction that warrants long-term follow-up, not a one-time laboratory note and discharge.

↑ Back to Table of Contents

Diagnosis

The diagnosis of selective immunoglobulin A deficiency is established by measuring serum immunoglobulin levels. The key criteria are:

  1. Serum immunoglobulin A below 7 mg/dL on at least two separate measurements.
  2. Age 4 years or older — physiologically low immunoglobulin A in infants and young children (under 4) does not constitute SIgAD; many infants have transient hypogammaglobulinemia that resolves spontaneously.
  3. Normal serum immunoglobulin G and immunoglobulin M — if immunoglobulin G is also significantly reduced, CVID must be considered and evaluated.
  4. Exclusion of secondary causes — review all medications (phenytoin, valproate, sulfasalazine, captopril, D-penicillamine, gold) before attributing immunoglobulin A deficiency to a primary immunodeficiency.

Additional diagnostic workup:

Measurement method is nephelometry (the standard for clinical immunoglobulin quantification). False low values can occur with paraprotein interference; if clinical suspicion is high despite low nephelometric immunoglobulin A, protein electrophoresis with immunofixation can clarify.

↑ Back to Table of Contents

Treatment

There is no therapy that restores immunoglobulin A production in selective immunoglobulin A deficiency. Management is therefore focused on preventing complications, treating infections promptly, monitoring for disease evolution, and avoiding iatrogenic harm from blood product exposure.

Asymptomatic SIgAD: No pharmacological treatment is needed. Counsel the patient about:

Recurrent sinopulmonary infections: Prophylactic antibiotics (e.g., azithromycin, trimethoprim-sulfamethoxazole) are appropriate for patients with two or more serious infections per year. Pneumococcal and influenza vaccination is strongly recommended — vaccine responses are generally adequate (immunoglobulin G-mediated) despite immunoglobulin A deficiency. Early and aggressive antibiotic treatment of acute infections prevents bronchiectasis.

IVIG therapy: Standard IVIG is generally contraindicated in SIgAD due to anaphylaxis risk from immunoglobulin A content. If replacement immunoglobulin is truly necessary (e.g., for evolution toward CVID with falling immunoglobulin G), use only immunoglobulin A-depleted IVIG preparations (immunoglobulin A content <1 µg/mL). Start at low doses with close monitoring in a facility equipped to manage anaphylaxis.

Celiac disease: A strict, lifelong gluten-free diet. Nutritional monitoring (iron, folate, vitamin B12, vitamin D, calcium) for malabsorption. Bone density monitoring (DEXA scan) given celiac-related osteoporosis risk.

Autoimmune manifestations: Treat according to the specific autoimmune diagnosis (e.g., levothyroxine for hypothyroidism, hydroxychloroquine and sun protection for systemic lupus erythematosus, disease-modifying antirheumatic drugs for rheumatoid arthritis (RA)). The underlying immunoglobulin A deficiency does not typically alter the treatment of the autoimmune condition itself, though some disease-modifying drugs (sulfasalazine, gold, D-penicillamine) can worsen immunoglobulin A deficiency and should be used cautiously.

Giardiasis: Metronidazole or tinidazole. Recurrent infections may require prolonged treatment or repeated courses. Avoid institutional water sources in endemic areas.

↑ Back to Table of Contents

Key Research Papers

The following peer-reviewed studies establish the foundational evidence base for selective immunoglobulin A deficiency — its epidemiology, pathogenesis, clinical associations, and management.

  1. Hammarström L, et al. (2000). Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clinical and Experimental Immunology — Search PubMed
  2. Yel L. (2010). Selective IgA deficiency. Journal of Clinical Immunology — Search PubMed
  3. Cunningham-Rundles C. (2001). Physiology of IgA and IgA deficiency. Journal of Clinical Immunology — Search PubMed
  4. Cataldo F, et al. (1998). IgA antiendomysium antibodies in identifying occult coeliac disease in children with type 1 diabetes mellitus. Gut — Search PubMed
  5. Kowalczyk D, et al. (1994). Anti-IgA antibodies in selective IgA deficiency and in various immunodeficiency disorders. Clinical and Experimental Immunology — Search PubMed
  6. Liblau RS, Bach JF. (1992). Selective IgA deficiency and autoimmunity. International Archives of Allergy and Immunology — Search PubMed
  7. Abolhassani H, et al. (2018). Worldwide variable immunodeficiency registry: report on the global distribution of primary immunodeficiency diseases. Journal of Clinical Immunology — Search PubMed
  8. Sekine H, et al. (2007). Role of TACI in CVID and IgA deficiency. Journal of Clinical Immunology — Search PubMed
  9. Aghamohammadi A, et al. (2009). Progression of selective IgA deficiency to common variable immunodeficiency. International Archives of Allergy and Immunology — Search PubMed
  10. Notarangelo L, et al. (2009). Primary immunodeficiencies: 2009 update. Journal of Allergy and Clinical Immunology — Search PubMed
  11. Wang N, et al. (2003). Heterozygous mutations in the gene encoding TACI are associated with common variable immunodeficiency and selective IgA deficiency. Nature Genetics — Search PubMed
  12. Schaffer FM, et al. (1991). Individuals with IgA deficiency and common variable immunodeficiency share polymorphisms of major histocompatibility complex class III genes. Proceedings of the National Academy of Sciences — PubMed PMID: 1351062

PubMed Topic Searches:

  1. Selective IgA deficiency — PubMed
  2. IgA deficiency + celiac disease — PubMed
  3. Anti-IgA antibodies and anaphylaxis — PubMed
  4. IgA deficiency to CVID progression — PubMed

↑ Back to Table of Contents

Connections

↑ Back to Table of Contents